On October 15, 2026, UBS started coverage of Solid Biosciences LLC (SLDB) at Buy.
Among five firms active over the past 90 days, five hold a bullish rating. As of October 30, 2026, 16 analysts place the consensus mean at $19.30, the median at $18.36 and the range at $14.14 to $27.30.
For Q4 FY2026, analysts expect EPS of -$0.44 and revenue of $0. The next earnings report is scheduled for March 4, 2027.
